Anavex Life Sciences (AVXL) Profit After Tax Growth (1y) (2017 - 2025)
Anavex Life Sciences (AVXL) Profit After Tax Growth (1y) (2017 - 2025) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PAT Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | 0.26% |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 17,802.13% |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | 59.59% |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | -107.76% |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | 101.22% |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | - |
| 10 | Anavex Life Sciences | 223.91 Mn | 92.16 Mn | - | 53.09% |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 53.09% |
| Sep 30, 2025 | 15.43% |
| Jun 30, 2025 | -8.42% |
| Mar 31, 2025 | -6.16% |
| Dec 31, 2024 | -40.47% |
| Sep 30, 2024 | -14.53% |
| Jun 30, 2024 | -8.28% |
| Mar 31, 2024 | 19.54% |
| Dec 31, 2023 | 33.53% |
| Sep 30, 2023 | 29.00% |
| Jun 30, 2023 | 8.79% |
| Mar 31, 2023 | -25.57% |
| Dec 31, 2022 | -19.20% |
| Sep 30, 2022 | -21.95% |
| Jun 30, 2022 | -21.48% |
| Mar 31, 2022 | -27.99% |
| Dec 31, 2021 | -38.54% |
| Sep 30, 2021 | -96.45% |
| Jun 30, 2021 | -56.94% |
| Mar 31, 2021 | -12.69% |